Why the study?
The study was conducted to evaluate risk factors leading to non-alcoholic fatty liver disease occurrence in women with polycystic ovary syndrome.
Population
586 women diagnosed with PCOS aged 13–35 years
Comparison
PCOS women with NAFLD vs those without
Design
Retrospective cohort study
Key result
In women with polycystic ovary syndrome, a baseline diagnosis of metabolic syndrome significantly increased the risk of subsequent non-alcoholic fatty liver disease occurrence (HR 5.6).
Authors
Loading...
May warrant NAFLD surveillance in PCOS with MetS; extends associations but requires prospective validation.
Cohort (n=586)
No
Effect estimate: HR 5.6 (95% CI 2.2-14.4)
p-value: p=<0.01
In women with PCOS, the presence of metabolic syndrome and hyperandrogenism are significant risk factors for the subsequent development of non-alcoholic fatty liver disease.
Won et al. (2021) conducted a cohort in Polycystic ovary syndrome (PCOS) (n=586). Metabolic syndrome (MetS) vs. No metabolic syndrome was evaluated on Subsequent NAFLD occurrence (HR 5.6, 95% CI 2.2-14.4, p=<0.01). In women with polycystic ovary syndrome, a baseline diagnosis of metabolic syndrome significantly increased the risk of subsequent non-alcoholic fatty liver disease occurrence (HR 5.6).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: